SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Glaukos Corporation (GKOS) News

Track canonical SquawkNews coverage tagged to GKOS, Glaukos Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol GKOS Asset equity Sector Markets 90 days 16 Last 184.38 Updated Jul 30, 2026, 12:31 PM UTC Open live news feed
L GKOS PT raised from $180 to $215, maintains Buy @ Truist GKOS PT raised from $180 to $215, maintains Buy @ Truist EQUITY | Jul 30, 2026, 12:31 PM UTC L GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to $680Mm—$700Mm vs. est. $629.98Mm; shares +8.3% EARNINGS | Jul 29, 2026, 08:38 PM UTC H PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7% PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%, RGR 4.8%, MOD +3.9%, ICLR +3.8%, ST +3.6%, MAX +2.6%, EQIX +2.4% after results EARNINGS | Jul 29, 2026, 08:27 PM UTC L Glaukos Raises FY2026 Sales Guidance from $620.000M-$635.000M to $680.000M-$700.000M vs $629.748M Est Glaukos (NYSE: GKOS ) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 million-$700.000 million vs $629.748 million estimate. EARNINGS | Jul 29, 2026, 08:17 PM UTC L GKOS - Glaukos Announces Second Quarter 2026 Financial Results GKOS - Glaukos Announces Second Quarter 2026 Financial Results EARNINGS | Jul 29, 2026, 08:13 PM UTC L GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $15 GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $150.9M, Q2 ADJ gross margin 85%, Glaukos Earnings Notes:, Outlook FY sales $680-70 EARNINGS | Jul 29, 2026, 08:07 PM UTC L RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra EQUITY | Jul 28, 2026, 11:52 AM UTC L GKOS Initiated Neutral at UBS GKOS Initiated Neutral at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishne GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishness @ Stifel EQUITY | Jul 28, 2026, 11:15 AM UTC L Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S EQUITY | Jul 28, 2026, 11:11 AM UTC L GKOS d/g Neutral @ UBS GKOS d/g Neutral @ UBS EQUITY | Jul 28, 2026, 09:15 AM UTC L GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel EQUITY | Jul 17, 2026, 11:06 AM UTC L Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing () -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 09, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,550,000. Following the Form 4 filing with the SEC, Thurman has control over a total GEOPOLITICS | Jul 14, 2026, 08:10 AM UTC L Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing () -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 06, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,500,000. Following the Form 4 filing with the SEC, Thurman has control over a total GEOPOLITICS | Jul 09, 2026, 07:06 AM UTC L Piper Sandler Reiterates Overweight on Glaukos, Maintains $165 Price Target Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE: GKOS ) with a Overweight and maintains $165 price target. EQUITY | Jul 01, 2026, 01:29 PM UTC L GKOS Completes Enrollment Glaukos completes patient enrollment in Phase 2 study of GLK-321 for Demodex Blepharitis EQUITY | Jun 25, 2026, 11:11 AM UTC